- Home
- Automated
- List of product information
- DUODART CAPSULES 0.5MG/0.4MG [SIN14181P]
DUODART CAPSULES 0.5MG/0.4MG [SIN14181P]
Active ingredients: DUODART CAPSULES 0.5MG/0.4MG
Last updated 26 October 2025
On this page
Product Info
DUODART CAPSULES 0.5MG/0.4MG
[SIN14181P]
Product information
Active Ingredient and Strength | DUTASTERIDE - 0.5 MG |
Dosage Form | CAPSULE |
Manufacturer and Country | CATALENT GERMANY SCHORNDORF GMBH – ENCAPSULATION - GERMANY |
Registration Number | SIN14181P |
Licence Holder | GLAXOSMITHKLINE PTE LTD |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | G04CA52 |
Indications
DUODART treats and prevents progression of benign prostatic hyperplasia (BPH) through alleviating symptoms, reducing prostate size (volume), improving urinary flow rate and reducing the risk of acute urinary retention (AUR) and the need for BPH-related surgery.
Dosage and Administration
Where appropriate, DUODART may be used to substitute concomitant dutasteride and tamsulosin hydrochloride in existing dual therapy to simplify treatment.
Where clinically appropriate, direct change from dutasteride or tamsulosin hydrochloride monotherapy to DUODART may be considered.
Adult males (including elderly)
The recommended dose of DUODART is one capsule (0.5 mg/0.4 mg) taken orally approximately 30 minutes after the same meal each day. Capsules should be swallowed whole and not chewed or opened. Contact with the contents of the dutasteride capsule contained within the hard-shell capsule may result in irritation of the oropharyngeal mucosa.
Patients should be advised that DUODART should not be taken on an empty stomach as this may increase the potential for cardiovascular related adverse events such as orthostatic hypotension (see Pharmacodynamics – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Renal impairment
The effect of renal impairment on dutasteride-tamsulosin pharmacokinetics has not been studied. However, no adjustment in dosage is anticipated for patients with renal impairment (see Pharmacokinetics – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Hepatic impairment
The effect of hepatic impairment on dutasteride-tamsulosin pharmacokinetics has not been studied (see Warnings and Precautions and Pharmacokinetics – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
DUODART is contraindicated in patients with severe hepatic impairment.
Contraindications
DUODART is contraindicated in:
patients with known hypersensitivity to dutasteride, other 5-alpha-reductase inhibitors, tamsulosin hydrochloride or any component of the preparation (see List of Excipients – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information)
patients with a history of orthostatic hypotension
patients with severe hepatic impairment (Child-Pugh scores >9)
patients with severe renal impairment (creatinine clearance less than 10mL/min)
combination with another α-1 adrenergic blocker
DUODART is contraindicated for use in women and children (see Pregnancy and Lactation – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).